Biotech · Public company · Cambridge, MA, US
Relay Therapeutics, Inc.
Ticker RLAY · SEC CIK 0001812364
Track this companyFree. Adds Relay Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials74 recruiting or active
Pipeline programs14From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline14
- CapivasertibPhase 3 · PIK3CA MutationClinicalTrials.gov · fetched Nov 12, 2026
- FulvestrantPhase 3 · PIK3CA MutationClinicalTrials.gov · fetched Nov 12, 2026
- ZovegalisibPhase 3 · PIK3CA MutationClinicalTrials.gov · fetched Nov 12, 2026
- RLY-2608Phase 2 · PIK3CA-Related Overgrowth Spectrum (PROS)ClinicalTrials.gov · fetched Nov 12, 2026
- RLY-8161Phase 2 · Advanced NRAS-Mutant MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- AbemaciclibPhase 1 · PIK3CA MutationClinicalTrials.gov · fetched Nov 12, 2026
- PalbociclibPhase 1 · PIK3CA MutationClinicalTrials.gov · fetched Nov 12, 2026
- Palbociclib 125mgPhase 1 · PIK3CA MutationClinicalTrials.gov · fetched Nov 12, 2026
- PF-07220060 100mgPhase 1 · PIK3CA MutationClinicalTrials.gov · fetched Nov 12, 2026
- RibociclibPhase 1 · PIK3CA MutationClinicalTrials.gov · fetched Nov 12, 2026
- Ribociclib 400mgPhase 1 · PIK3CA MutationClinicalTrials.gov · fetched Nov 12, 2026
- Ribociclib 600mgPhase 1 · PIK3CA MutationClinicalTrials.gov · fetched Nov 12, 2026
- RLY-2608Phase 1 · PIK3CA MutationClinicalTrials.gov · fetched Nov 12, 2026
- RLY-5836Phase 1 · PIK3CA MutationClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials7
- A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid TumorsPHASE1_PHASE2 · RECRUITING · started Mar 9, 2026ClinicalTrials.gov NCT07584226 · fetched Nov 12, 2026
- Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast CancerPHASE3 · RECRUITING · started Aug 26, 2025ClinicalTrials.gov NCT06982521 · fetched Nov 12, 2026
- A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)PHASE2 · RECRUITING · started Jun 13, 2025ClinicalTrials.gov NCT06789913 · fetched Nov 12, 2026
- First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid TumorsPHASE1 · COMPLETED · started Mar 29, 2023ClinicalTrials.gov NCT05759949 · fetched Nov 12, 2026
- First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast CancerPHASE1 · RECRUITING · started Dec 8, 2021ClinicalTrials.gov NCT05216432 · fetched Nov 12, 2026
- A Study to Assess Virtual Reality by Healthcare Providers: A Pilot StudyNA · COMPLETED · started Jan 1, 2021ClinicalTrials.gov NCT04622527 · fetched Nov 12, 2026
- Early Childhood Obesity Programming by Intrauterine Growth RestrictionCOMPLETED · started Sep 1, 2018ClinicalTrials.gov NCT03402139 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 4, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 9, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 21, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 19, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 27, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 16, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 11, 2026 · fetched Nov 12, 2026